Pashna N Munshi1, David H Vesole1,2, Andrew St Martin3, Omar Davila3, Shaji Kumar4, Muzaffar Qazilbash5, Nina Shah6, Parameswaran N Hari3, Anita D'Souza3. 1. Georgetown University Hospital, Washington, DC. 2. John Theurer Cancer Center at Hackensack UMC, Hackensack, New Jersey. 3. Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin. 4. Mayo Clinic Rochester, Rochester, Minnesota. 5. MD Anderson Cancer Center, Houston, Texas. 6. Division of Hematology-Oncology, University of California-San Francisco, San Francisco, California.
Abstract
BACKGROUND: Consolidative autologous hematopoietic stem cell transplantation (AHCT) is commonly used for patients with multiple myeloma (MM). We studied AHCT use and outcomes in patients with MM ≥75 years old. METHODS: Patients with MM ≥75 years old receiving AHCT between 2013 and 2017 in the United States were identified using the Center for International Blood and Marrow Transplant Research database. Relapse and/or progression (REL), progression-free survival (PFS), and overall survival (OS) were modeled using Cox proportional hazards models. Covariates used were age, sex, Karnofsky performance score (KPS), HCT-comorbidity index (HCT-CI), International Staging System and/or Durie-Salmon stage, high-risk cytogenetics, melphalan dose, and disease status at and 1 year after transplant. AHCT utilization rate using the Surveillance, Epidemiology, and End Results database was used to estimate specific incidence among ≥75 years old by race and gender. RESULTS: Of 360 patients, 63% were male, 84% were White, 56% had KPS <90, and 57% had HCT-CI ≥3. The 100-day transplant-related mortality was 1% (0%-2%) with a 2-year REL rate of 27% (95% confidence interval [CI], 22%-33%), PFS of 66% (95% CI, 60%-72%), and OS of 83% (95% CI, 78%-87%). On multivariate analysis, only high-risk cytogenetics was associated with REL risk and decreased PFS. In White males, transplant utilization rate was 5.2%-5.8% compared to 3.5%-4.0% in African American males (P = .02). There was 3.37-3.79% transplant utilization in White females compared to 1.88-2.12% in African American females (P < .01). CONCLUSIONS: The use of AHCT was associated with excellent 2-year outcomes in this selected MM population ≥75 years old. Transplant utilization for patients ≥75 years old remains low with significant racial and gender disparities.
BACKGROUND: Consolidative autologous hematopoietic stem cell transplantation (AHCT) is commonly used for patients with multiple myeloma (MM). We studied AHCT use and outcomes in patients with MM ≥75 years old. METHODS: Patients with MM ≥75 years old receiving AHCT between 2013 and 2017 in the United States were identified using the Center for International Blood and Marrow Transplant Research database. Relapse and/or progression (REL), progression-free survival (PFS), and overall survival (OS) were modeled using Cox proportional hazards models. Covariates used were age, sex, Karnofsky performance score (KPS), HCT-comorbidity index (HCT-CI), International Staging System and/or Durie-Salmon stage, high-risk cytogenetics, melphalan dose, and disease status at and 1 year after transplant. AHCT utilization rate using the Surveillance, Epidemiology, and End Results database was used to estimate specific incidence among ≥75 years old by race and gender. RESULTS: Of 360 patients, 63% were male, 84% were White, 56% had KPS <90, and 57% had HCT-CI ≥3. The 100-day transplant-related mortality was 1% (0%-2%) with a 2-year REL rate of 27% (95% confidence interval [CI], 22%-33%), PFS of 66% (95% CI, 60%-72%), and OS of 83% (95% CI, 78%-87%). On multivariate analysis, only high-risk cytogenetics was associated with REL risk and decreased PFS. In White males, transplant utilization rate was 5.2%-5.8% compared to 3.5%-4.0% in African American males (P = .02). There was 3.37-3.79% transplant utilization in White females compared to 1.88-2.12% in African American females (P < .01). CONCLUSIONS: The use of AHCT was associated with excellent 2-year outcomes in this selected MM population ≥75 years old. Transplant utilization for patients ≥75 years old remains low with significant racial and gender disparities.
Authors: Joseph Mikhael; Nofisat Ismaila; Matthew C Cheung; Caitlin Costello; Madhav V Dhodapkar; Shaji Kumar; Martha Lacy; Brea Lipe; Richard F Little; Anna Nikonova; James Omel; Namrata Peswani; Anca Prica; Noopur Raje; Rahul Seth; David H Vesole; Irwin Walker; Alexander Whitley; Tanya M Wildes; Sandy W Wong; Tom Martin Journal: J Clin Oncol Date: 2019-04-01 Impact factor: 44.544
Authors: Manish Sharma; Mei-Jie Zhang; Xiaobo Zhong; Muneer H Abidi; Görgün Akpek; Ulrike Bacher; Natalie S Callander; Angela Dispenzieri; César O Freytes; Henry C Fung; Robert Peter Gale; Cristina Gasparetto; John Gibson; Leona A Holmberg; Tamila L Kindwall-Keller; Thomas R Klumpp; Amrita Y Krishnan; Heather J Landau; Hillard M Lazarus; Sagar Lonial; Angelo Maiolino; David I Marks; Paulette Mehta; Joseph R Mikhael Med; Taiga Nishihori; Richard Olsson; Muthalagu Ramanathan; Vivek Roy; Bipin N Savani; Harry C Schouten; Emma Scott; Jason Tay; Luen Bik To; David H Vesole; Dan T Vogl; Parameswaran Hari Journal: Biol Blood Marrow Transplant Date: 2014-07-18 Impact factor: 5.742
Authors: Jean El Cheikh; Elias Kfoury; Boris Calmels; Claude Lemarie; Anne-Marie Stoppa; Reda Bouabdallah; Diane Coso; Jean-Marc Schiano De Collela; Patrick Ladaique; Jean-Albert Gastaut; Mohamad Mohty; Christian Chabannon; Didier Blaise Journal: Hematol Oncol Stem Cell Ther Date: 2011
Authors: Antonio Palumbo; Sara Bringhen; Heinz Ludwig; Meletios A Dimopoulos; Joan Bladé; Maria V Mateos; Laura Rosiñol; Mario Boccadoro; Michele Cavo; Henk Lokhorst; Sonja Zweegman; Evangelos Terpos; Faith Davies; Christoph Driessen; Peter Gimsing; Martin Gramatzki; Roman Hàjek; Hans E Johnsen; Fernando Leal Da Costa; Orhan Sezer; Andrew Spencer; Meral Beksac; Gareth Morgan; Hermann Einsele; Jesus F San Miguel; Pieter Sonneveld Journal: Blood Date: 2011-08-12 Impact factor: 22.113
Authors: Shaji K Kumar; David Dingli; Martha Q Lacy; Angela Dispenzieri; Suzanne R Hayman; Francis K Buadi; S Vincent Rajkumar; Mark R Litzow; Morie A Gertz Journal: Am J Hematol Date: 2008-08 Impact factor: 10.047
Authors: Pashna N Munshi; David Vesole; Artur Jurczyszyn; Jan Maciej Zaucha; Andrew St Martin; Omar Davila; Vaibhav Agrawal; Sherif M Badawy; Minoo Battiwalla; Saurabh Chhabra; Edward Copelan; Mohamed A Kharfan-Dabaja; Nosha Farhadfar; Siddhartha Ganguly; Shahrukh Hashmi; Maxwell M Krem; Hillard M Lazarus; Ehsan Malek; Kenneth Meehan; Hemant S Murthy; Taiga Nishihori; Rebecca L Olin; Richard F Olsson; Jeffrey Schriber; Sachiko Seo; Gunjan Shah; Melhem Solh; Jason Tay; Shaji Kumar; Muzaffar H Qazilbash; Nina Shah; Parameswaran N Hari; Anita D'Souza Journal: Cancer Date: 2020-09-23 Impact factor: 6.860
Authors: Pashna N Munshi; Yue Chen; Kwang W Ahn; Farrukh T Awan; Amanda Cashen; Geoffrey Shouse; Mazyar Shadman; Paul Shaughnessy; Joanna Zurko; Frederick L Locke; Aaron M Goodman; Jose C Villaboas Bisneto; Craig Sauter; Mohamad A Kharfan-Dabaja; Gabrielle Meyers; Samantha Jaglowski; Alex Herrera; Mehdi Hamadani Journal: Transplant Cell Ther Date: 2022-05-21